Bladder Cancer: Our Clinical Trials

At Memorial Sloan Kettering, our physicians and researchers continue to investigate innovative techniques, new drugs, and advanced treatments for bladder cancer. You may be eligible for one of many clinical trials under way that are testing new approaches in chemotherapy, surgery, or radiation therapy.

The trials can also help doctors compare the effectiveness of prevention strategies or other aspects of your care. Our Bladder Cancer Research Registry of Genetic and Clinical Information (also known as Genotype-Phenotype Urothelial Cancer Study), for example, is a database of genetic and clinical information that is helping doctors learn about risk factors for the disease as well as genetic markers that may predict a person’s response to treatment.

If you are eligible to participate in a clinical trial for bladder cancer, you may have access to new therapies that are not yet widely available. Our bladder cancer treatment team is experienced in selecting people with bladder cancer who are most likely to benefit from a particular therapy and can help guide you through the process of enrolling in the most appropriate clinical trial.

Here you can find a continually updated listing of Memorial Sloan Kettering’s current clinical trials for bladder cancer. To learn more about a study, choose from the list below.

Showing 14 trials
Title Investigatorsort icon
A Phase I Study of Debio1347 in Patients with Advanced Cancers Containing FGFR Alterations
[Protocol 13-131]
Voss, Martin, MD
A Phase II Study of Docetaxel Alone or with OGX-427 in Patients with Recurrent or Refractory Urothelial Cancers
[Protocol 13-127]
Rosenberg, Jonathan, MD
A Phase II Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
[Protocol 14-090]
Rosenberg, Jonathan, MD
A Phase I Study of ASG-22CE in Patients with Metastatic Urothelial Cancers Containing Nectin-4
[Protocol 14-108]
Rosenberg, Jonathan, MD
A Phase II Study of Mocetinostat in Patients with Advanced Urothelial Cancers Containing Certain Genetic Mutations
[Protocol 14-242]
Rosenberg, Jonathan, MD
A Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
[Protocol 10-031]
Kollmeier, Marisa, MD
A Phase II Study of Neratinib in Patients with Solid Tumors Containing Mutated HER2
[Protocol 13-140]
Hyman, David, MD
A Phase I/II Study of Everolimus and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Non-Muscle-Invasive Bladder Cancer
[Protocol 10-165]
Dalbagni, Guido, MD
A Phase III Study Comparing Standard versus Extended Pelvic Lymph Node Removal During Bladder Cancer Surgery
[Protocol 12-049]
Bochner, Bernard, MD
A Phase II Study of Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer
[Protocol 12-071]
Bajorin, Dean, MD
A Phase II Study of Gemcitabine, Carboplatin, and Panitumumab Given Before Surgery in Patients with Muscle-Invasive Bladder Cancer
[Protocol 10-103]
Bajorin, Dean, MD
A Phase I Study of BGJ398 in Patients with Advanced Urothelial Cancers
[Protocol 14-218]
Bajorin, Dean, MD
A Genotype-Phenotype Urothelial Cancer Study
[Protocol 09-025]
Bajorin, Dean, MD
A Study Comparing Standard Fluid Management with a Device for Goal-Directed Fluid Management in Patients Undergoing Bladder Removal Surgery
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-069]
Arslan Carlon, Vittoria, MD